Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 05, 2015 9:43 PM ET

Biotechnology

Company Overview of Five Prime Therapeutics, Inc.

Company Overview

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company’s product candidates include FPA008, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ib clinical trials for the treatment of rheumatoid arthritis; and in pre-IND stage for pigmented villonodular synovitis and multiple cancers in combination with nivolumab. Its product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor 2b and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039/GSK3052230, a fus...

Two Corporate Drive

South San Francisco, CA 94080

United States

Founded in 2001

123 Employees

Phone:

415-365-5600

Fax:

415-365-5601

Key Executives for Five Prime Therapeutics, Inc.

Founder, Chief Executive Officer, President and Director
Age: 66
Total Annual Compensation: $525.0K
Chief Medical Officer and Senior Vice President
Age: 57
Total Annual Compensation: $382.1K
Chief Business Officer, Senior Vice President and Director
Age: 46
Total Annual Compensation: $364.0K
Compensation as of Fiscal Year 2014.

Five Prime Therapeutics, Inc. Key Developments

Five Prime Therapeutics, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 08:30 AM

Five Prime Therapeutics, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 08:30 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Lewis T. Williams, Founder, Chief Executive Officer, President and Director.

bluebird bio Enters into License Agreement with Five Prime Therapeutics

bluebird bio, Inc. and Five Prime Therapeutics, Inc. have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using Five Prime's human antibodies to an undisclosed cancer target for hematologic malignancies and solid tumors. Five Prime Therapeutics is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics for cancer and inflammatory diseases, while bluebird bio is a developer of gene therapies for severe genetic disorders. Under the terms of the agreement, Five Prime will provide bluebird bio exclusive rights to its novel human antibodies to the target, and bluebird bio will leverage its proprietary lentiviral gene therapy platform and CAR T capabilities to develop CAR T therapies against the target.

bluebird bio, Inc. and Five Prime Therapeutics, Inc. Enter into an Exclusive License Agreement to Research, Develop and Commercialize Chimeric Antigen Receptor

bluebird bio, Inc. and Five Prime Therapeutics, Inc. announced that they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using Five Prime's proprietary human antibodies to an undisclosed cancer target for hematologic malignancies and solid tumors. Under the terms of the agreement, Five Prime will provide bluebird bio exclusive rights to its novel human antibodies to the target, and bluebird bio will leverage its proprietary lentiviral gene therapy platform and CAR T capabilities to develop CAR T therapies against the target. Financial terms of the agreement include a $1.5 million upfront payment and subsequent milestone payments to Five Prime, which together could total over $130 million per licensed product if certain development, regulatory, and commercial milestones are achieved. Five Prime is also eligible to receive tiered royalties on product sales. bluebird bio will conduct and fund clinical development as well as regulatory and commercial activities.

Similar Private Companies By Industry

Company Name Region
Tissue Harvest Systems, LLC United States
VasoGenix Pharmaceuticals, Inc. United States
The Michigan Biotechnology Institute United States
Biosynexus Incorporated United States
Nucelis Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Five Prime Therapeutics, Inc., please visit www.fiveprime.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.